Talk:Senotherapy

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Untitled 2020 comment[edit]

Senotherapeutics: clinical interventions to restore senescent cells to their normal function as they were prior to the onset of senescent changes.

The definition of senotherapeutics should exclude senolytics, as the latter doesn't aim to intervene therapeutically in senescent cells, but rather seeks to remove them. In some respects, senolytic therapy is the opposite of senotherapeutics, in that senolytic therapy seeks to destroy, rather than improve the function of, senescent cells. — Preceding unsigned comment added by Michael Fossel (talk • contribs) 13:11, 19 October 2020 (UTC)[reply]

I think the name of the topic is "Senolytics" with a plural. - Tony — Preceding unsigned comment added by 49.237.23.253 (talk) 09:24, 31 October 2020 (UTC)[reply]

Senescence‐associated secretory phenotype[edit]

IMHO, there needs to be an article on the Senescence‐associated secretory phenotype (SASP). There are numerous references that exist for it, and it seems fairly significant. This should also help with decreasing the length of the corresponding point in the current article. This would be done by moving a mention of many of the SASP inhibitors to the new article. --Hyperforin 01:08, 7 February 2016 (UTC)

Senescence-associated secretory phenotype now exists. --Ben Best:Talk 10:40, 4 August 2020 (UTC)[reply]